Trial Profile
A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor In Combination With AG-013736 (Axitinib) In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; PF 4856884 (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 12 Jul 2019 This trial has been completed in UK according to European Clinical Trials Database
- 21 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 11 Oct 2012 Planned End Date changed from 1 Dec 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.